Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,939 INR
Change Today -74.85 / -3.72%
Volume 225.8K
As of 7:07 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

natco pharma ltd (NTCPH) Snapshot

Open
2,025
Previous Close
2,014
Day High
2,090
Day Low
1,920
52 Week High
04/7/15 - 2,710
52 Week Low
05/20/14 - 706.30
Market Cap
64.4B
Average Volume 10 Days
234.3K
EPS TTM
32.16
Shares Outstanding
33.2M
EX-Date
02/24/15
P/E TM
60.3x
Dividend
5.00
Dividend Yield
0.26%
Current Stock Chart for NATCO PHARMA LTD (NTCPH)

Related News

No related news articles were found.

natco pharma ltd (NTCPH) Related Businessweek News

No Related Businessweek News Found

natco pharma ltd (NTCPH) Details

NATCO Pharma Limited operates as a pharmaceutical company in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic segments, such as anti-neoplastics, anti-depressants, anti-migraine, anti- osteoporosis, anti-asthma, proton pump inhibitors, and therapeutic peptides. It also provides generic oncology products for the treatment of hematology and solid tumors under the brand names of Geftinat, Erlonat, Veenat, and Sorafenat. In addition, it provides formulations, such as Ondansetron, Anastrozole, Letrozole, Trihexyphenidyl, Cholorquine Phosphate, and Citalopram, as well as is engaged in the retail pharmacy business and contract manufacturing activities. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Founded in 1981

natco pharma ltd (NTCPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natco pharma ltd (NTCPH) Key Developments

Natco Pharma Receives Approval for Generic 'Sofosbuvir' Tablets in India

Natco Pharma has received an approval for generic Sofosbuvir tablets, 400 mg, from Drugs Controller General. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi. It will market generic Sofosbuvir under its brand HEPCINAT and through strategic partners in India. It plans to price its generic medicine at an MRP of INR 19,900 for a bottle of 28 tablets and expects to launch in India very soon. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences.

Natco Pharma Limited Launches the First Generic Version of Sofosbuvir in Nepal

Natco Pharma Limited announced that it has launched the first generic version of sofosbuvir in Nepal. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi®. Natco priced its generic medicine at an MRP of INR 19,900 for a bottle of 28 tablets in Nepal. Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI). Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

Natco Pharma Limited, Q3 2015 Earnings Call, Feb 12, 2015

Natco Pharma Limited, Q3 2015 Earnings Call, Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTCPH:IN 1,938.65 INR -74.85

NTCPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Momenta Pharmaceuticals Inc $20.13 USD +0.04
Teva Pharmaceutical Industries Ltd $64.41 USD +1.16
View Industry Companies
 

Industry Analysis

NTCPH

Industry Average

Valuation NTCPH Industry Range
Price/Earnings 61.3x
Price/Sales 7.9x
Price/Book 8.1x
Price/Cash Flow 43.8x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATCO PHARMA LTD, please visit www.natcopharma.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.